A drug used to prevent and to treat influenza virus infections. It blocks the release of the virus from infected cells. It is a type of antiviral agent.
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.
Zanamivir is an influenza (flu) antiviral drug that is approved for use in the United States. The approved form of zanamivir is available as an orally inhaled powder. An intravenous form of zanamivir is available for compassionate use. Antiviral drugs are prescription medications that can be used to treat flu illness. Zanamivir is commercially available as Relenza®. It is a neuraminidase (NA) inhibitor class antiviral drug that targets and inhibits the NA surface proteins of an influenza virus.